Applied Therapeutics, Inc.

Equities

APLT

US03828A1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
4.67 ^USD	+1.52%		+2.64%	+39.40%

09/05	Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
09/05	Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000	MT

APPLIED THERAPEUTICS INC. : Change in Directors or Principal Officers (form 8-K)

January 29, 2022 at 03:04 am IST

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On January 27, 2022, Charles Silberstein notified Applied Therapeutics, Inc. (the "Company") of his intention to resign as Chief Financial Officer and Principal Financial Officer of the Company, effective January 28, 2022, in order to pursue another opportunity. Mr. Silberstein's resignation does not result from any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Company has appointed Chids Mahadevan, Vice President Finance and Principal Accounting Officer, as the interim Principal Financial Officer. Mr. Mahadevan will serve as the interim Principal Financial Officer while the Company conducts its search for a new Chief Financial Officer.

Latest news about Applied Therapeutics, Inc.

Applied Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Posts Q1 Revenue $190,000	09/05	MT
Applied Therapeutics, Inc. Announces Management Changes	15/04	CI
Applied Therapeutics Shares Slip 13% After FDA Extends Drug Review	29/03	DJ
FDA Extends Review Period for Applied Therapeutics Genetic Disease Treatment	29/03	DJ
Applied Therapeutics Gets NDA Review Period Extension for Galactosemia Treatment -- Shares Fall After Hours	29/03	MT
US FDA extends review of Applied Therapeutics' genetic disease drug	29/03	RE
Applied Therapeutics, Inc. Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia	29/03	CI
RBC Initiates Applied Therapeutics at Outperform, Speculative Risk With $12 Price Target, Sees Lead Drug Govorestat 'Well-Positioned for Success'	26/03	MT
UBS Adjusts Applied Therapeutics Price Target to $13 From $12, Maintains Buy Rating	15/03	MT
UBS Adjusts Applied Therapeutics Price Target to $12 From $4, Maintains Buy Rating	06/03	MT
Applied Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Earnings Flash (APLT) APPLIED THERAPEUTICS Reports Q4 Revenue $10M	06/03	MT
Applied Therapeutics, Inc. announced that it has received $99.997998 million in funding from a group of investors	01/03	CI
Applied Therapeutics' NDA for Govorestat Accepted by FDA; Launches $100 Million Private Placement; Shares Jump	28/02	MT
Applied Therapeutics Shares Surge on FDA Review, $100 Million Funding Round	28/02	DJ
Leerink Partners Initiates Applied Therapeutics at Outperform Rating $12 Price Target	22/02	MT
Sector Update: Health Care Stocks Higher Late Afternoon	17/02	MT
Sector Update: Health Care	17/02	MT
Applied Therapeutics Says Phase 3 Trial of Govorestat Meets Interim Primary Goal; Shares Rise	17/02	MT
Transcript : Applied Therapeutics, Inc. - Special Call	15/02
Applied Therapeutics, Inc. Announces Positive Interim 12-Month Results from the Ongoing Phase 3 Inspire Trial	15/02	CI
Applied Therapeutics, Inc. Announces Positive Results from 12-Month Interim Analysis of Govorestat (At-007) in the Ongoing Inspire Phase 3 Trial in Sorbitol Dehydrogenase Deficiency	15/02	CI
Wall Street ends topsy-turvy day marginally up	06/01	RE
Top MIdday Decliners	06/01	MT

Chart Applied Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Companyâs lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor (ARI) for the treatment of central nervous system (CNS) rare metabolic diseases, including Galactosemia, Sorbitol Dehydrogenase (SORD) Deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of Diabetic Cardiomyopathy (DbCM) a fatal fibrosis of the heart. It has completed a Phase I/II clinical trial evaluating AT-001 in approximately 120 patients with type 2 diabetes, in which no drug-related adverse effects or tolerability issues were observed. The preclinical pipeline also includes AT-003, an ARI designed to cross through the back of the eye when dosed orally, for the treatment of Diabetic retinopathy.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Applied Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.67 USD

Average target price

11.4 USD

Spread / Average Target

+144.11%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
APPLIED THERAPEUTICS, INC.	+39.40%	526M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	122B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.49B
BIONTECH SE	-23.86%	19.4B
GENMAB A/S	-19.03%	16.24B
BEIGENE, LTD.	-20.90%	15.4B
WUXI APPTEC CO., LTD.	-46.14%	15.15B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.52B

Bio Therapeutic Drugs